PepGen Raises $125M After Record Rally, Powering Muscular Dystrophy Breakthroughs
PepGen Inc. secures $125 million in a $5/share offering after record‑setting Phase 2 results for its muscular dystrophy therapy, boosting stock to a 52‑week high and attracting strong investor confidence.
3 minutes to read
